MAPT and dementia: Karikari et al. further confirmed the increase in plasma p-tau 181 levels in patients with AD and MCI patients that developed AD and showed that plasma p-tau 181 can discriminate AD dementia from not only normal young and older adults, but also FTD, VaD, progressive supranuclear palsy, corticobasal syndrome, Parkinson’s disease, and multiple system atrophy [83].